(Q43807992)

27 November 2017

Thalidomide-induced normalization of serum ALT levels in a patient with hepatitis C. (English)

1 reference

27 November 2017

0 references

Raufman JP

1

1 reference

PubMed ID

11721782

27 November 2017

Lamps LW

series ordinal

2

1 reference

PubMed ID

11721782

27 November 2017

language of work or name

English

0 references

publication date

1 November 2001

1 reference

The American Journal of Gastroenterology

27 November 2017

1 reference

27 November 2017

96

1 reference

27 November 2017

3209-3211

1 reference

27 November 2017

11

1 reference

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

27 November 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.05289.X

Host genetic factors influence disease progression in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.05289.X

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.05289.X

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.05289.X

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.05289.X

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.05289.X

10.1111/J.1572-0241.2001.05289.X

21 January 2018

Identifiers

DOI

1 reference

27 November 2017

1 reference

PubMed ID

11721782